Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 274 adjuvant nivolumab versus placebo in high-risk invasive urothelial carcinoma
NL-OMON59113Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Nivolumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59113.